The Clinical Trials Unit Resource (CTUR) component ofthe CDU/UCI^ Cancer Center Partnership will be charged with the overarching goal of enhancing minority participation in clinical research and clinical trials. The accomplishment of this goal will further develop the institutional capacity at CDU in the area of cancer-related clinical trials by leveraging existing clinical research facilities and resources. Specifically, the partnership will enhance the established Clinical Research Center (CRC) at CDU;the clinical trials component ofthe CRC, called the Clinical Center for Research Excellence (CCRE), was developed to enhance CDU's infrastructure for clinical studies and is headed by Dr. Mayer Davidson. The CDU-UCLA partnership will continue to build upon the current infrastructure to enhance the ability to conduct effective clinical studies in cancer heath disparities. The specific objectives of the Resources activities are as follows:
Specific Aim 1 : Enhance the recruitment and retention of racial and ethnic minorities into clinical trials related to cancer at the CRC;
Specific Aim 2 : Provide training and assistance in the design, development, and execution of CDU clinical cancer research studies;
Specific Aim 3 : Communicate and solicit feedback regarding clinical trials with the community via the Outreach Program;
and Specific Aim 4 : Employ external reviewers to assess the quality and strength ofthe clinical results. These reviewers will be engaged at the eariiest onset to provide input in the development of clinical studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Sarkissyan, Marianna; Wu, Yanyuan; Chen, Zujian et al. (2014) Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer 120:1387-93
Li, Jihong; Vootukuri, Spandana; Shang, Yi et al. (2014) RUC-4: a novel ?IIb?3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 34:2321-9
Mathews Griner, Lesley A; Guha, Rajarshi; Shinn, Paul et al. (2014) High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 111:2349-54
Lin, Lehang; Gaut, Daria; Hu, Kaishun et al. (2014) Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474). Int J Oncol 44:557-62
Okamoto, Ryoko; Gery, Sigal; Kuwayama, Yoshio et al. (2014) Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. Int J Cancer 134:207-17
Ceribelli, Michele; Kelly, Priscilla N; Shaffer, Arthur L et al. (2014) Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 111:11365-70
Maxwell, Annette E; Young, Sandra; Rabelo Vega, Roena et al. (2014) Training Mixtec promotores to assess health concerns in their community: a CBPR pilot study. J Immigr Minor Health 16:310-3
Gery, S; Koeffler, H P (2013) Role of the adaptor protein LNK in normal and malignant hematopoiesis. Oncogene 32:3111-8
Yin, D; Ogawa, S; Kawamata, N et al. (2013) miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32:1155-63
Elshimali, Yahya I; Khaddour, Husseina; Sarkissyan, Marianna et al. (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14:18925-58

Showing the most recent 10 out of 16 publications